Yang Hae Park

Title: Innovations by Yang Hae Park in Pharmaceutical Science

Introduction

Yang Hae Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical science, particularly in developing compositions for treating various medical conditions. With a total of 2 patents, his work focuses on innovative solutions that address critical health issues.

Latest Patents

Yang Hae Park's latest patents include a pharmaceutical composition for preventing or treating inflammatory bowel disease. This invention acts as a functional antagonist for S1PR1 and S1PR4, specifically targeting S1P receptors. The composition includes a sphingolipid compound that does not cause cardiovascular side effects while effectively preventing or treating inflammatory bowel disease. Another significant patent involves a pharmaceutical composition for preventing or treating alopecia areata, also acting as a functional antagonist for S1PR1 and S1PR4. This composition contains a sphingolipid compound that is effective in treating alopecia areata without causing cardiovascular side effects.

Career Highlights

Yang Hae Park is associated with Nextgen Bioscience Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing safe and effective treatments for patients.

Collaborations

Yang has collaborated with notable colleagues, including Bong Yong Lee and Eun Jeong Kim, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yang Hae Park's contributions to pharmaceutical science demonstrate his dedication to improving health outcomes through innovative inventions. His patents reflect a focus on safety and efficacy, addressing significant medical challenges.